Royal Adelaide Hospital

Aethlon Medical reports Q2 FY2024 financials, highlights progress in oncology trials in Australia and India, including enrollment of first two patients in Hemopurifier® cancer trial. Company implements cost-cutting measures, appoints James Frakes as permanent CEO, and maintains cash balance of $6.9 million. Conference call scheduled for November 13, 2024.

Aethlon Medical enrolled the first patient in its Australian Hemopurifier® trial for solid tumors unresponsive to anti-PD-1 antibodies, aiming to improve response rates from 30-40%.

Dr. Shiva Akbarzadeh's lab at Monash University creates engineered human skin for severe burn patients, showing positive results with quick wound closure and minimal scarring. The lab is part of ongoing research to reduce the need for autografts by growing skin cells from small samples, using hydrogel sheets to support grafts. This work continues a tradition of Australian burns research, aiming to improve healing and quality of life for burn victims.

Aethlon Medical expands equity incentive plan, approved by stockholders, to attract and retain talent. The company also gains ethics approval for Hemopurifier trials in India and Australia, while reporting a net loss of $2.6 million in Q1 2025. Despite financial challenges, Aethlon holds more cash than debt and has seen recent positive market sentiment.

Solid tumors market projected to reach $375.4B by 2034 with 7.45% CAGR. Aethlon Medical activates Hemopurifier trial at Royal Adelaide Hospital for solid tumor patients resistant to anti-PD-1 therapies. Immuneering reports positive initial data for IMM-1-104 in pancreatic cancer. FDA approves new immunotherapy combinations for endometrial cancer from AstraZeneca, Merck, and GlaxoSmithKline. Roche's trastuzumab deruxtecan receives accelerated approval for HER2-positive solid tumors.

Aethlon Medical's Hemopurifier® trial at Royal Adelaide Hospital begins screening patients with solid tumors unresponsive to anti-PD-1 antibodies. The trial aims to assess safety, feasibility, and dose-finding, with plans to activate additional sites in Australia and potentially India.